Accretropin – New Injectable Growth Hormone Approved by FDA

Today, the U.S. Food and Drug Administration (FDA) approved a new recombinant growth hormone manufactured by the Canadian drug company, Cangene, and designed for subcutaneous injection. The brand name for Cangene’s injectable growth hormone is Accretropin. Accretropin has an identical amino acid sequence to natural human growth hormone produced in the pituitary. It was approved for treatment of children with short stature and Turner’s Syndrome (a chromosomal disorder in girls resulting in short stature and infertility). Cangene submitted the new drug application (NDA) to the FDA in July 2006.

 Accretropin joins several other 191-amino acid sequence growth hormone brands currently approved by the FDA including Nutropin AQ, Saizen, Genotropin, Humatrope, Serostim, Zorbtive, Norditropin and Zomacton

About the author

Millard

MESO-Rx | Website

Millard writes about anabolic steroids and performance enhancing drugs and their use and impact in sport and society. He discusses the medical and non-medical uses of anabolic-androgenic steroids while advocating a harm reduction approach to steroid education.